Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • About us
    • Leadership Team
    • Partners
    • Business Development & Licensing
    • Compliance & Code of Conduct
    • Contacts
  • Molecular Imaging
    • How It Works
    • Value of Molecular Imaging
  • Research & Development
    • Neuro-Imaging
    • Onco-Imaging
    • Cardiovascular-Imaging
  • Products
  • News
    • Current News
    • Careers

DuChemBio Co. Ltd. and Life Molecular Imaging SA sign a Manufacturing and Supply Agreement for Alzheimer’s Disease Diagnostic Radiopharmaceutical for The Philippines

11. July 201911. July 2019lifemolecular

Read more: NeuraCeq (florbetaben) will be soon available in The Philippines

Life Molecular Imaging and National Cyclotron and PET Centre, Chulabhorn Royal Academy, Thailand Announce a Collaboration for Brain PET Imaging with NeuraCeq and PI-2620

15. June 201915. June 2019lifemolecular

Read more: Brain imaging research study with amyloid and tau PET to investigate aging Thai individuals aiming for development of models for a healthier life in the Thai society

Life Molecular Imaging and Institut de Radiofarmàcia Aplicada de Barcelona (IRAB) Announce a Strategic Partnership for Production of NeuraCeq and PI-2620 in Barcelona

26. April 201926. April 2019lifemolecular

Read more: Improved supply capabilities of NeuraCeq in the Communities of Catalonia and Aragon through the collaboration with IRAB. Investigational tau imaging agent PI-2620 added to the imaging biomarker platform for research studies.

Life Molecular Imaging Applauds the Publication of the IDEAS Study Aim I Results

8. April 20198. April 2019lifemolecular

Read more: Publication of IDEAS study aim 1 results shows that Amyloid PET Imaging was associated with changes in clinical management for Medicare beneficiaries with MCI, dementia, cognitive impairment or Alzheimer’s Disease

Life Molecular Imaging Announces Presentation of New Clinical Data of the Next Generation Tau PET Tracer PI-2620 at the AD/PD 2019 Conference

27. March 201927. March 2019lifemolecular

Readmore: New clinical data of PI-2620 Tau-PET highlight the sensitive detection of Tau pathology in neurodegenerative diseases .

Life Molecular Imaging and XingImaging Announce PI-2620 Tau PET Tracer Production in Mainland China

26. October 201826. October 2018lifemolecular

Readmore: Life Molecular Imaging (LMI) and XingImaging announced that production of LMI’s 18F-labeled Tau PET imaging agent PI-2620 has commenced at XingImaging sites in China. 

Life Molecular Imaging and SOFIE announce PI-2620 Tau PET Tracer Production in SOFIE Radiopharmacy Network

13. September 201813. September 2018lifemolecular

Readmore: PI-2620 Tau PET tracer production for clinical trial supply has commenced in SOFIE Radiopharmacy Network

Piramal Imaging becomes Life Molecular Imaging

27. August 201827. August 2018lifemolecular

Readmore: Following the recent acquisition by Alliance Medical Group, Piramal Imaging is being renamed Life Molecular Imaging

Alliance Medical completes the purchase of Piramal Imaging

26. June 201821. August 2018lifemolecular

Readmore: Alliance-Medical-completes-the-purchase-of-Piramal-Imaging

Posts navigation

Newer posts →
© Copyright 2018 Life Molecular Imaging
Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection
Imprint / Data protection
Contact
Scroll to Top
 

Loading Comments...